drugset / Trial / NCT02547870

A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics

NCT02547870

Phase 1 Completed 61 enrolled Janssen Infectious Diseases BVBA
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the single-dose pharmacokinetics of rilpivirine (RPV) after intramuscular (IM) injection of rilpivirine long-acting parenteral formulation (RPV-LA) and 'aged' RPV-LA, in healthy adult participants.

Timeline

Start
2015-08-14
Primary completion
2016-04-26
Completion
2016-04-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Rilpivirine Small molecule 25 mg Oral
Subject Rilpivirine Small molecule 600 mg Oral